67 listed pharmaceutical companies have invested more than 5.3 billion yuan

2015-04-03

    In the pharmaceutical industry，R & D ability is an important evaluation indicator to measure the future development of a pharmaceutical company，R & D expenditure in the proportion of operating income (hereinafter referred to as R & D accounting) is one of the common specific parameters。With the strong support of national policy，The R & D level of domestic biomedical companies has improved。According to Fllow Shun Data, it shows，As of March 25，Total 67 listed companies in the pharmaceutical industry announced the 2014 R & D expenses，Total about 5.356 billion yuan。Compared with 4.271 billion yuan in 2013，Research from Stake Sports Bettingstake betting appthe pharmaceutical company listed in 2014 ...